8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2018

TELIGENT, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-08568	01-0355758
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of incorporation)		Identification No.)

105 Lincoln Avenue

Buena, New Jersey 08310

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (856) 697-1441

IGI Laboratories, Inc.

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Officers of Teligent, Inc. (the “Company”) will present an investor presentation to members of the investment community beginning on Wednesday, January 10, 2018.  A copy of the investor presentation to be used during these programs is attached to this Current Report on Form 8-K as Exhibit 99.1 and is also available in the “Investors” section of the Company’s website at www.teligent.com.

In accordance with General Instruction B.2 on Form 8-K, the information set forth in this Item 7.01 and the investor presentation attached to this report as Exhibit 99.1 is “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended.

The investor presentation attached hereto as Exhibit 99.1 contains certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout the presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our inability to meet current or future regulatory requirements in connection with existing or future Abbreviated New Drug Applications (“ANDAs”); our inability to achieve profitability; our failure to obtain U.S. Food and Drug Administration (“FDA”) approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in the presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in the presentation as a result of, among other factors, the factors referenced in the “Risk Factors” section of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2016 and the “Risk Factors” sections of our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2016, August 8, 2016 and November 8, 2016, respectively.

In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in the presentation, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in the presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of the presentation, except as required by law.

You should read carefully our “Forward-Looking Statements” and the factors described in the “Risk Factors” sections of our Annual Report on Form 10-K to better understand the risks and uncertainties inherent in our business.

Item 9.01.  Financial Statements and Exhibits.

(d)           Exhibits.

Exhibit No.	Description
99.1	Investor Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TELIGENT, INC.
	By:	/s/ Jenniffer Collins
	Name:	Jenniffer Collins
	Title:	Chief Financial Officer
Date: January 10, 2018

EX-99.1

JP Morgan Healthcare Conference January 10, 2018 Jason Grenfell-Gardner │CEO Nasdaq Global Select: TLGT

Safe Harbor 1 Except for historical facts, the statements in this presentation, as well as oral statements or other written statements made or to be made by Teligent, Inc., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties. For example, without limitation, statements about the Company’s anticipated growth and future operations, the current or expected market size for its products, the success of current or future product offerings and the research and development efforts and the Company’s ability to file for and obtain U.S. Food and Drug Administration (FDA) approvals for future products, are forward-looking statements. Forward-looking statements are merely the Company’s current predictions of future events. The statements are inherently uncertain, and actual results could differ materially from the statements made herein. There is no assurance that the Company will achieve the sales levels that will make its operations profitable or that FDA filings and approvals will be completed and obtained as anticipated. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its latest Annual Report on Form 10–K and its latest Quarterly Report on Form 10-Q. The Company assumes no obligation to update its forward-looking statements to reflect new information and developments.

Key Investment Highlights Teligent is a “market disruptor” in alternative dosage form generics Focused on Topical, Injectable, Complex and Ophthalmic (TICO) markets Led by a proven and dynamic management team Significant investment in R&D has resulted in a high-value pipeline State of the art topical and injectable manufacturing infrastructure Strong historical sales growth Solid foundation to support sustainable, profitable growth 1 2 3 4 5 6 7 2

Teligent at-a-glance 3 Teligent is a high-growth generics company that develops and markets a diversified product portfolio focused on alternative dosage forms Diversified Product Portfolio • 58 products sold throughout North America − 28 injectables and topicals in US − 30 injectables in Canada Deep Development Pipeline • 32 ANDAs pending at FDA representing ~$2B IMS opportunity • >40 products in active development State of the Art Manufacturing • ~$55M invested in facility expansion and upgrade −High-speed topical filling −New sterile injectable capability Skilled and Dedicated Employees • 200+ employees worldwide • Presence in New Jersey, Toronto, and Estonia

• Limited API supply • Complex formulations • Specialized manufacturing requirements • Fewer market players compared to commoditized dosage forms, such as oral solids • Frequent supply disruptions = more opportunities • Ability to foresee and quickly react to disruptions − Broad portfolio − Robust development capabilities • Quality finished dose manufacturing − Manufacture 24 of 28 products in US − Capacity to manufacture 30 of 32 ANDA products Alternative dosage form generics are susceptible to market disruption 4 Alternative dosage form markets have unique characteristics… Resulting in advantageous market dynamics Teligent is positioned to benefit as a market disruptor

Teligent is focused on Topical, Injectable, Complex and Ophthalmic (TICO) markets 5 Dosage Form Description Current Teligent Strength Topical • Core strength • Established development and manufacturing capabilities • 24 commercial products; 30 filed ANDAs Injectable • Investing in manufacturing – first commercial product out of new facility in 2019 • Expanded development capabilities • 34 products commercialized in the US and Canada Complex • Leverages existing development and commercial know- how • First product, representing >$200M IMS market opportunity, filed in 2017 Ophthalmic • Leverages sterile injectable expertise and retail commercial channel presence • First ophthalmic filed in 2017, and three additional products under active development with CMO

Led by a proven and dynamic executive leadership team 6 Jason Grenfell-Gardner President & Chief Executive Officer Jenniffer Collins Chief Financial Officer Steve Richardson Chief Scientific Officer Martin Wilson General Counsel

Future R&D • Historical R&D spend as a percent of revenue has been far greater than the industry average • R&D as a percent of revenue will decline going forward • Accelerate development throughput − Leverage previously approved ANDAs/NDAs, including 23 injectables − Accelerated path to market via Prior Approval Supplement (PAS) pathway where possible Teligent has historically made outsized investments in R&D 7 $13 $17 $13 $7 $3 0% 5% 10% 15% 20% 25% 30% 35%$30 $0 $10 $20 $15 $5 $25 % of Revenue R&D Spend $, Millions 2014 20162013 2015 Q1-Q3 2017

R&D investment has resulted in a deep, high-value pipeline 8 Cumulative US ANDA Submissions and Approvals As of December 31, 2017 8 13 19 31 36 32 1911 2012 2013 20172016 2 2014 1 2015 Pending ANDAsApproved ANDAs % Total Addressable Market of US Submissions 100% = ~$2.0 billion* GDUFA Year 3-5 10% Pre-GDUFA Year 3 90% * IQVIA TAM as of November 2017

Declining ANDA review cycle times bodes well for near-term pipeline approvals 9 2022 39 GDUFA Yr 5 GDUFA Yr 3 GDUFA Yr 4 Pre- GDUFA Yr 3 57 33 22 11 1 GDUFA Yr 5 Pre- GDUFA Yr 3 GDUFA Yr 3 GDUFA Yr 4 Average ANDA Approval Times Months Average Open ANDA Submission Times Months Average review times for Teligent ANDA submissions are declining Stage set for near-term Teligent ANDA pipeline approvals ANDA Approvals 9 6 4 0 Open ANDA Submissions 6 6 6 11 3 GDUFA II Yr 1

Robust topical and injectable manufacturing infrastructure 10 Investing ~$55M in the facility expansion Background • Located in Buena, New Jersey • Currently manufacture 24 Teligent- label topical products • Facility expansion >3x original plant − Now almost 110,000 square feet − Increased topical capacity − New sterile injectable capability Expansion Milestones 2016 – Commenced construction 2017 – Construction completed Mid-2018 – File first injectable product 2H2018 – FDA prior approval inspection 2019 – Launch first injectable product ~4-8M initial injectable unit capacity with increase to ~40M with addition of high-speed line

Strong sales growth has subsidized investment for sustained growth 11 $52 $66 $44 $32 $18 $2 $10 $3 $6 $1 2013 20152014 Q1-Q3 20172016 Annual Financial Performance $, Millions Adj. EBITDANet Revenue Full Year 2017 Net Revenue Guidance $65-67* * Guidance as of November 6, 2017

Teligent-label product sales have exhibited strong growth 12 49 32 20 7 2014 20152013 2016 CAGR +88% Annual Teligent-Label Product Net Sales $, Millions Key Growth Drivers: • 19 Teligent-label products launched in US since 2012 − Launched first Teligent-label product in December 2012 • Acquired econazole nitrate cream in 2013 • Launched TICO strategy in 2014 • Acquired 3 injectable products (Fortaz®, Zantac® and Zinacef®) in 2015 • Acquired Alveda Pharmaceuticals, which was generating ~$16M CAD in net sales, in 2015

Solid foundation to support sustainable, profitable growth Focus on Investment 2012 - 2017 Focus on Profitability 2018 and beyond • Invested >$150M* over the past 5 years • Transitioned from contract services to Teligent-label products • Strengthened development capabilities and grew product pipeline • Expanded manufacturing capabilities beyond topicals into injectables • Harvest pipeline and accelerate new product launches • Strengthen commercial capabilities and improve margins • Focus on lean operations and enhancing profitability • Accelerate product development by leveraging R&D and enhanced manufacturing capabilities * Investment defined as R&D, CapEx and M&A

Key 2018 Objectives 14 • Enhance profitability − Disciplined cost control • Increase development throughput − Leverage previously launched ANDAs/NDAs • Accelerate ANDA approvals − 11 ANDAs with GDUFA goal dates in 1Q and 2Q • Strengthen commercial presence − Expand commercial team – enhance retail and build institutional presence • Operationalize new injectable facility − First injectable filing, triggering PAI